Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
KPTI 
Karyopharm Therapeutics Inc (KPTI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: KPTI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $25.92
1 Year Target Price $25.92
| 2 | Strong Buy |
| 3 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -48.57% | Avg. Invested days 26 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 51.33M USD | Price to earnings Ratio - | 1Y Target Price 25.92 |
Price to earnings Ratio - | 1Y Target Price 25.92 | ||
Volume (30-day avg) 6 | Beta 0.28 | 52 Weeks Range 3.51 - 16.95 | Updated Date 08/15/2025 |
52 Weeks Range 3.51 - 16.95 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -14.84 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Earnings Date
Report Date 2025-08-11 | When - | Estimate -3.9072 | Actual -4.0652 |
Profitability
Profit Margin -90.02% | Operating Margin (TTM) -64.3% |
Management Effectiveness
Return on Assets (TTM) -45.16% | Return on Equity (TTM) -891.05% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 179242442 | Price to Sales(TTM) 0.37 |
Enterprise Value 179242442 | Price to Sales(TTM) 0.37 | ||
Enterprise Value to Revenue 1.31 | Enterprise Value to EBITDA -1.85 | Shares Outstanding 8671280 | Shares Floating 7918871 |
Shares Outstanding 8671280 | Shares Floating 7918871 | ||
Percent Insiders 6.29 | Percent Institutions 51 |
Upturn AI SWOT
Karyopharm Therapeutics Inc
Company Overview
History and Background
Karyopharm Therapeutics Inc. was founded in 2008. It is a commercial-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases.
Core Business Areas
- Oncology: Focuses on developing and commercializing therapies for hematologic and solid tumor cancers. Their lead product is XPOVIO (selinexor).
Leadership and Structure
The leadership team is headed by Richard Paulson, Ph.D., as President and Chief Executive Officer. The organizational structure is typical of a biotech company, with departments for R&D, clinical development, commercial operations, and finance.
Top Products and Market Share
Key Offerings
- XPOVIO (selinexor): XPOVIO is an oral Selective Inhibitor of Nuclear Export (SINE) compound. It is approved for multiple myeloma, diffuse large B-cell lymphoma (DLBCL), and endometrial cancer. Revenue for 2023 was approximately $120 million. Competitors in myeloma include therapies from GSK (BLENREP), JNJ (DARZALEX), and BMS (REVLIMID/POMALYST). In DLBCL, it competes with standard chemotherapy regimens and CAR-T therapies. In endometrial cancer XPOVIO competitors are dostarlimab-gxly, pembrolizumab, and chemotherapy.
Market Dynamics
Industry Overview
The oncology market is large and growing, driven by an aging population and advances in cancer treatment. There is significant competition among pharmaceutical companies to develop and commercialize innovative cancer therapies.
Positioning
Karyopharm is positioned as a company focused on developing novel therapies for cancers with unmet needs. Their SINE technology offers a unique mechanism of action. However, they are a smaller player compared to larger pharmaceutical companies.
Total Addressable Market (TAM)
The global oncology market is projected to reach over $500 billion in the coming years. Karyopharm targets specific sub-segments within this large market with XPOVIO, estimated at multi-billion dollars based on current indications. XPOVIO's TAM increases as it continues to get approved for more indications.
Upturn SWOT Analysis
Strengths
- Novel SINE technology
- Approved product (XPOVIO) for multiple indications
- Experienced management team
- Focus on unmet medical needs
Weaknesses
- Reliance on a single product (XPOVIO)
- Limited financial resources compared to larger pharma companies
- Intense competition in the oncology market
- Past regulatory hurdles and CRLs impacting stock price
Opportunities
- Expanding indications for XPOVIO
- Developing new SINE compounds
- Partnering with larger pharmaceutical companies
- Entering new markets
Threats
- Competition from existing and emerging therapies
- Regulatory setbacks
- Patent expirations
- Pricing pressure
Competitors and Market Share
Key Competitors
- JNJ
- GSK
- BMS
Competitive Landscape
Karyopharm faces intense competition from larger pharmaceutical companies with more established oncology portfolios. Their competitive advantage lies in their novel SINE technology. However, XPOVIO's adoption is still dependent on demonstrating superior clinical outcomes compared to existing therapies.
Growth Trajectory and Initiatives
Historical Growth: Revenue growth has been driven by increased sales of XPOVIO.
Future Projections: Analysts project continued revenue growth as Karyopharm expands indications for XPOVIO and potentially introduces new products.
Recent Initiatives: Focus on expanding XPOVIO's label, conducting clinical trials for new indications, and managing operating expenses.
Summary
Karyopharm Therapeutics is a biotech company with a novel drug, XPOVIO, approved for several cancer indications. The company has shown revenue growth, but continues to operate at a loss. Karyopharm's reliance on a single product and competition in the oncology market are significant risks. Successful expansion of XPOVIO's indications and new product development will be crucial for long-term success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Karyopharm Therapeutics Investor Relations, SEC Filings (10K, 10Q), Analyst Reports, Market Research Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Karyopharm Therapeutics Inc
Exchange NASDAQ | Headquaters Newton, MA, United States | ||
IPO Launch date 2013-11-06 | President, CEO & Director Mr. Richard A. Paulson M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 279 | Website https://www.karyopharm.com |
Full time employees 279 | Website https://www.karyopharm.com | ||
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. In addition, the company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, the company has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.